<DOC>
	<DOCNO>NCT00485069</DOCNO>
	<brief_summary>Ropinirole Hydrochloride ( ROP ) grant approval treatment Parkinson 's Disease ( PD ) 20 October 2006 . ROP expect use long term clinical practice . However , long-term clinical data ROP administer three time daily currently available Japanese patient , clinical experience ROP &gt; 10mg/day limited . For reason , study design multicenter open-label uncontrolled study . This study evaluate long-term efficacy ( Japanese Unified Parkinson 's Disease Rating Scale ( UPDRS ) , Awake time spend `` Off '' / '' On '' , Modified Hoehn &amp; Yahr stage , Schwab-England scale , Proportion subject remain study Clinical Global Impression ( CGI ) ) long-term safety ROP administer three time daily PD patient .</brief_summary>
	<brief_title>REQUIP ( Ropinirole Hydrochloride ) IR Long-Term Phase 4 Study</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Inclusion criterion : Subjects eligible enrollment study must meet following criterion . Note inpatient outpatient eligible . Patients diagnosis PD ( include juvenile parkinsonism ) Modified Hoehn &amp; Yahr Stages I IV . Patients receive another dopamine agonist least 4 week prior start screen phase expect benefit conversion ROP . Age : 20 year ( time write informed consent ) . Informed consent : Patients able give write informed consent person ( i.e. , patient capable give write informed consent ) . Gender : Male female Females childbearing potential eligible enrollment study , subject negative pregnancy test start screen phase agree conduct pregnancy test protocolspecified visit study use one follow acceptable method contraception properly accurately : Abstinence Oral contraceptive , either combined progestogen alone Injectable progestogen Implants levonorgestrel Estrogenic vaginal ring ( Caution : This use cautiously , blood concentration study drug may increase . ) Percutaneous contraceptive patch Intrauterine device ( IUD ) intrauterine system ( IUS ) Male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study , male sole partner subject ) Double barrier method : condom occlusive cap ( diaphragm cervical / vault cap ) plus spermicidal agent ( foam/gel/film/cream/suppository ) Exclusion criterion : Subjects meet follow criterion must enrol study : Patients present serious medical condition PD ( e.g. , cardiac , hepatic renal disorder hematopoietic disorder ) . Serious define Grade 3 rule accord Classification Severity Adverse Experiences . Patients postural hypotension subjective symptom ( e.g. , dizziness syncope ) . Patients serious psychiatric symptom ( e.g. , confusion , hallucination , delusion , abnormal behavior ) ( include symptom cause antiPD drug ) within 6 month ( 26 week ) prior write informed consent . Patients initiate follow drug within 4 week start screen phase dose regimen drug change within 4 week start screen phase . Ldopa ( +DCI ) ( NOTE : This apply monotherapy group . ) Anticholinergic agent : trihexyphenidyl hydrochloride , piroheptine hydrochloride , mazaticol hydrochloride , metixene hydrochloride , biperiden , profenamine amantadine hydrochloride droxidopa citicoline selegiline hydrochloride entacapone zonisamide Patients severe dementia Japanese UPDRS Part I ( mentation , behavior , mood ) score 3 4 . Female patient pregnant lactating , may pregnant , plan pregnancy study period within 30 day last dose study drug . Patients history drug allergy ingredient ROP tablet . Patients receive surgical treatment PD past ( e.g. , pallidectomy , deep brain stimulation ) . Patients treat investigational product within 12 week prior start screen phase . Patients , judgement investigator ( subinvestigator ) , evidence alcohol drug abuse . Others investigator ( subinvestigator ) considers ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Ropinirole hydrochloride</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Dopamine agonist</keyword>
</DOC>